Hee-Jong Hwang
Hee-Jong Hwang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Young-Jin Son
A&J Science Co., Ltd., 80 Chumbok Ro, Dong Gu, Daegu 41061, Republic of Korea
5 shared publications Dahyun Kim
A&J Science Co., Ltd, Daegu, Republic of Korea
3 shared publicationsMarco A. Ciufolini
Department of Chemistry, University of British Columbia, Vancouver, Canada
3 shared publications- Marco A. Ciufolini
Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
3 shared publications Hyunjoo Pai
Department of Internal Medicine, Hanyang University College of Medicine, 232 Wangsimri Ro, Seongdong-Gu, Seoul 04763, Republic of Korea
2 shared publicationsJin-Hwan Kwak
School of Life Science, Handong Global University, 558 Handong Ro, Heunghae-Eup, Buk-Gu, Pohang 37554, Republic of Korea
2 shared publications
Latest Publications
- 16 December 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (1) , 314-325
A Novel Thiopeptide Exhibits In Vitro and In Vivo Synergistic Antibacterial Activity with Macrolide Against Mycobacterium avium Complex Infection
The limitations of the current standard therapy for pulmonary diseases caused by Mycobacterium avium complex (MAC) underscore the urgent need for novel therapeutic agents. Among potential candidates, thiopeptide antibiotics have attracted attention due to their antibacterial activity but their poor solubility has limited clinical application. In this study, we developed AJ-099, a thiopeptide derivative with improved solubility and enhanced antibacterial potency. The in vitro antibacterial activity of AJ-099 was confirmed across macrolide-susceptible and- resistant clinical isolates, with minimum inhibitory concentration values consistently falling within the range of ≤0.125-0.5 μg/mL. In addition, AJ-099 exhibited a marked growth inhibition against both macrolide-susceptible and -resistant MAC clinical isolates in macrophages. Importantly, AJ-099 displayed synergistic effects in combination with clarithromycin (CLR), a macrolide drug, which resulted in significantly greater reductions in intracellular MAC burden compared to either agent alone. The synergistic effect was consistently observed in vivo, where the AJ-099 and CLR combination achieved superior bacterial clearance and reduced lung inflammation to the current standard therapy consisting of CLR, ethambutol, and rifampicin. Collectively, these results highlight that AJ-099 in combination with macrolides is a promising candidate for treating MAC pulmonary infections. Moreover, its potent activity against macrolide-resistant MAC strains suggests it may offer an effective therapeutic option for refractory MAC pulmonary infections.
- 16 December 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (1) , 314-325
A Novel Thiopeptide Exhibits In Vitro and In Vivo Synergistic Antibacterial Activity with Macrolide Against Mycobacterium avium Complex Infection
The limitations of the current standard therapy for pulmonary diseases caused by Mycobacterium avium complex (MAC) underscore the urgent need for novel therapeutic agents. Among potential candidates, thiopeptide antibiotics have attracted attention due to their antibacterial activity but their poor solubility has limited clinical application. In this study, we developed AJ-099, a thiopeptide derivative with improved solubility and enhanced antibacterial potency. The in vitro antibacterial activity of AJ-099 was confirmed across macrolide-susceptible and- resistant clinical isolates, with minimum inhibitory concentration values consistently falling within the range of ≤0.125-0.5 μg/mL. In addition, AJ-099 exhibited a marked growth inhibition against both macrolide-susceptible and -resistant MAC clinical isolates in macrophages. Importantly, AJ-099 displayed synergistic effects in combination with clarithromycin (CLR), a macrolide drug, which resulted in significantly greater reductions in intracellular MAC burden compared to either agent alone. The synergistic effect was consistently observed in vivo, where the AJ-099 and CLR combination achieved superior bacterial clearance and reduced lung inflammation to the current standard therapy consisting of CLR, ethambutol, and rifampicin. Collectively, these results highlight that AJ-099 in combination with macrolides is a promising candidate for treating MAC pulmonary infections. Moreover, its potent activity against macrolide-resistant MAC strains suggests it may offer an effective therapeutic option for refractory MAC pulmonary infections.
- 20 August 2024
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 40 (10) , 1-15
Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides
Antimicrobial resistance poses a significant threat to humanity, and the development of new antibiotics is urgently needed. Our research has focused on thiopeptide antibiotics such as micrococcin P2 (MP2) and derivatives thereof as new anti-infective agents. Thiopeptides are sulfur-rich, structurally complex substances that exhibit potent activity against Gram-positive pathogens and Mycobacteria species, including clinically resistant strains. The clinical development of thiopeptides has been hampered by the lack of efficient synthetic platforms to conduct detailed structure-activity relationship studies of these natural products. The present contribution touches upon efficient synthetic routes to MP2 that laid the groundwork for clinical translation. The medicinal chemistry campaign on MP2 has been guided by computational molecular dynamic simulations and parallel investigations to improve drug-like properties, such as enhancing the aqueous solubility and optimizing antibacterial activity. Such endeavors have enabled identification of promising lead compounds, AJ-037 and AJ-206, against Mycobacterium avium complex (MAC). Extensive in vitro studies revealed that these compounds exert potent activity against MAC species, a subspecies of non-tuberculous mycobacteria (NTM) that proliferate inside macrophages. Two additional pre-clinical candidates have been identified: AJ-024, for the treatment of Clostridioides difficile infections, and AJ-147, for methicillin-resistant Staphylococcus aureus impetigo. Both compounds compare quite favorably with current first-line treatments. In particular, the ability of AJ-147 to downregulate pro-inflammatory cytokines adds a valuable dimension to its clinical use. In light of above, these new thiopeptide derivatives are well-poised for further clinical development. Graphical abstracts
- 20 August 2024
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 40 (10) , 1-15
Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides
Antimicrobial resistance poses a significant threat to humanity, and the development of new antibiotics is urgently needed. Our research has focused on thiopeptide antibiotics such as micrococcin P2 (MP2) and derivatives thereof as new anti-infective agents. Thiopeptides are sulfur-rich, structurally complex substances that exhibit potent activity against Gram-positive pathogens and Mycobacteria species, including clinically resistant strains. The clinical development of thiopeptides has been hampered by the lack of efficient synthetic platforms to conduct detailed structure-activity relationship studies of these natural products. The present contribution touches upon efficient synthetic routes to MP2 that laid the groundwork for clinical translation. The medicinal chemistry campaign on MP2 has been guided by computational molecular dynamic simulations and parallel investigations to improve drug-like properties, such as enhancing the aqueous solubility and optimizing antibacterial activity. Such endeavors have enabled identification of promising lead compounds, AJ-037 and AJ-206, against Mycobacterium avium complex (MAC). Extensive in vitro studies revealed that these compounds exert potent activity against MAC species, a subspecies of non-tuberculous mycobacteria (NTM) that proliferate inside macrophages. Two additional pre-clinical candidates have been identified: AJ-024, for the treatment of Clostridioides difficile infections, and AJ-147, for methicillin-resistant Staphylococcus aureus impetigo. Both compounds compare quite favorably with current first-line treatments. In particular, the ability of AJ-147 to downregulate pro-inflammatory cytokines adds a valuable dimension to its clinical use. In light of above, these new thiopeptide derivatives are well-poised for further clinical development. Graphical abstracts
- Open Access
Therapies from Thiopeptides
The first part of this contribution describes solutions that were developed to achieve progressively more efficient syntheses of the thiopeptide natural products, micrococcins P1 and P2 (MP1–MP2), with an eye toward exploring their potential as a source of new antibiotics. Such efforts enabled investigations on the medicinal chemistry of those antibiotics, and inspired the development of the kinase inhibitor, Masitinib®, two candidate oncology drugs, and new antibacterial agents. The studies that produced such therapeutic resources are detailed in the second part. True to the theme of this issue, “Organic Synthesis and Medicinal Chemistry: Two Inseparable Partners”, an important message is that the above advances would have never materialized without the support of curiosity-driven, academic synthetic organic chemistry: a beleaguered science that nonetheless has been—and continues to be—instrumental to progress in the biomedical field.
Open AccessTherapies from Thiopeptides
The first part of this contribution describes solutions that were developed to achieve progressively more efficient syntheses of the thiopeptide natural products, micrococcins P1 and P2 (MP1–MP2), with an eye toward exploring their potential as a source of new antibiotics. Such efforts enabled investigations on the medicinal chemistry of those antibiotics, and inspired the development of the kinase inhibitor, Masitinib®, two candidate oncology drugs, and new antibacterial agents. The studies that produced such therapeutic resources are detailed in the second part. True to the theme of this issue, “Organic Synthesis and Medicinal Chemistry: Two Inseparable Partners”, an important message is that the above advances would have never materialized without the support of curiosity-driven, academic synthetic organic chemistry: a beleaguered science that nonetheless has been—and continues to be—instrumental to progress in the biomedical field.
- 5 October 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (20) , 14263-14277
Identification of Micrococcin P2-Derivatives as Antibiotic Candidates against Two Gram-Positive Pathogens
Thiopeptides exhibit potent antimicrobial activity against Gram-positive pathogens by inhibiting bacterial protein synthesis. Micrococcins are among the structurally simpler thiopeptides, but they have not been exploited in detail. This research involved a computational simulation of micrococcin P2 (MP2) docking in parallel with the structure-activity relationship (SAR) studied. The incorporation of particular nitrogen heterocycles in the side chain of MP2 enhances the antimicrobial activity. Micrococcin analogues 6c and 6d thus proved to be more effective against impetigo and C. difficile infection (CDI), respectively, as compared to current first-line treatments. Compound 6c also showed a shorter treatment period than that of a first-line treatment for impetigo. This may be attributed to its ability to downregulate pro-inflammatory cytokines. Compound 6d had no observed recurrence for C. difficile and exerted a minimal impact on the beneficial gut microbiome. Their pharmacokinetic properties and low toxicity profile make these compounds ideal candidates for the treatment of impetigo and CDI and validate their involvement in preclinical development.
- 5 October 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (20) , 14263-14277
Identification of Micrococcin P2-Derivatives as Antibiotic Candidates against Two Gram-Positive Pathogens
Thiopeptides exhibit potent antimicrobial activity against Gram-positive pathogens by inhibiting bacterial protein synthesis. Micrococcins are among the structurally simpler thiopeptides, but they have not been exploited in detail. This research involved a computational simulation of micrococcin P2 (MP2) docking in parallel with the structure-activity relationship (SAR) studied. The incorporation of particular nitrogen heterocycles in the side chain of MP2 enhances the antimicrobial activity. Micrococcin analogues 6c and 6d thus proved to be more effective against impetigo and C. difficile infection (CDI), respectively, as compared to current first-line treatments. Compound 6c also showed a shorter treatment period than that of a first-line treatment for impetigo. This may be attributed to its ability to downregulate pro-inflammatory cytokines. Compound 6d had no observed recurrence for C. difficile and exerted a minimal impact on the beneficial gut microbiome. Their pharmacokinetic properties and low toxicity profile make these compounds ideal candidates for the treatment of impetigo and CDI and validate their involvement in preclinical development.
- 24 January 2023
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 18 (2) , 265-272
Heterologous Synthesis and Characterization of Thiocillin IV
Micrococcin P1 and P2 are thiopeptides with a wide range of biological functions including antibacterial and antimalarial activities. We previously demonstrated optimized enzymatic sequences for the exclusive and scalable biosynthesis of micrococcin P2. Thiocillin IV is predicted to be the congener of O-methylated micrococcin P2, but the exact structure has not been elucidated. In this study, we report the first scalable biosynthesis and full structural characterization of thiocillin IV, a 26-membered thiopeptide. This was achieved by generating a recombinant plasmid by inserting tclO, a gene encoding an O-methyltransferase, and genes responsible for micro-coccin P2 production and incorporating them into a Bacillus strain. With the incorporation of precursor peptide genes and optimal culture conditions, production reached 2.4 mg/L of culture. The purified thiocillin IV structure was identified as O-methylated micrococcin P2 at the 8-Thr position, and its promising biological activity toward various Gram-positive pathogens was observed. This study provides tclO-mediated site-selective methylation and opens a biotechnological opportunity to produce selective thiopeptides.
- 24 January 2023
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 18 (2) , 265-272
Heterologous Synthesis and Characterization of Thiocillin IV
Micrococcin P1 and P2 are thiopeptides with a wide range of biological functions including antibacterial and antimalarial activities. We previously demonstrated optimized enzymatic sequences for the exclusive and scalable biosynthesis of micrococcin P2. Thiocillin IV is predicted to be the congener of O-methylated micrococcin P2, but the exact structure has not been elucidated. In this study, we report the first scalable biosynthesis and full structural characterization of thiocillin IV, a 26-membered thiopeptide. This was achieved by generating a recombinant plasmid by inserting tclO, a gene encoding an O-methyltransferase, and genes responsible for micro-coccin P2 production and incorporating them into a Bacillus strain. With the incorporation of precursor peptide genes and optimal culture conditions, production reached 2.4 mg/L of culture. The purified thiocillin IV structure was identified as O-methylated micrococcin P2 at the 8-Thr position, and its promising biological activity toward various Gram-positive pathogens was observed. This study provides tclO-mediated site-selective methylation and opens a biotechnological opportunity to produce selective thiopeptides.
- 11 July 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (8) , 1928-1935
Micrococcin P2 Targets Clostridioides difficile
Clostridioides difficile infection is a global public health threat. Extensive in vitro assays using clinical isolates have identified micrococcin P2 (MP2, 1) as a particularly effective anti-C. difficile agent. MP2 possesses a mode of action that differs from other antibiotics and pharmacokinetic properties that render it especially promising. Its time-kill studies have been investigated using hypervirulent C. difficile ribotype 027. DSS (dextran sulfate sodium)-induced in vivo mouse studies with that strain indicate that 1 is better than vancomycin and fidaxomicin. Thus, micrococcin P2 is a valuable platform to be exploited for the development of new anti-C. difficile antibiotics.
- 11 July 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (8) , 1928-1935
Micrococcin P2 Targets Clostridioides difficile
Clostridioides difficile infection is a global public health threat. Extensive in vitro assays using clinical isolates have identified micrococcin P2 (MP2, 1) as a particularly effective anti-C. difficile agent. MP2 possesses a mode of action that differs from other antibiotics and pharmacokinetic properties that render it especially promising. Its time-kill studies have been investigated using hypervirulent C. difficile ribotype 027. DSS (dextran sulfate sodium)-induced in vivo mouse studies with that strain indicate that 1 is better than vancomycin and fidaxomicin. Thus, micrococcin P2 is a valuable platform to be exploited for the development of new anti-C. difficile antibiotics.
- Open Access
- 19 May 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (5) , 623
Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target Clostridioides difficile
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of new drugs is sparse at best. Thus, there is a clear and urgent need for new antibiotics against that organism. Herein, we disclose that AJ-024, a nitroimidazole derivative of a 26-membered thiopeptide, is a promising anti-C. difficile lead compound. Despite their unique mode of action, thiopeptides remain largely unexploited as anti-infective agents. AJ-024 combines potent in vitro activity against various strains of C. difficile with a noteworthy safety profile and desirable pharmacokinetic properties. Its time-kill kinetics against a hypervirulent C. difficile ribotype 027 and in vivo (mouse) efficacy compare favorably to vancomycin, and they define AJ-024 as a valuable platform for the development of new anti-C. difficile antibiotics.
- 19 May 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (5) , 623
Open AccessNitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target Clostridioides difficile
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of new drugs is sparse at best. Thus, there is a clear and urgent need for new antibiotics against that organism. Herein, we disclose that AJ-024, a nitroimidazole derivative of a 26-membered thiopeptide, is a promising anti-C. difficile lead compound. Despite their unique mode of action, thiopeptides remain largely unexploited as anti-infective agents. AJ-024 combines potent in vitro activity against various strains of C. difficile with a noteworthy safety profile and desirable pharmacokinetic properties. Its time-kill kinetics against a hypervirulent C. difficile ribotype 027 and in vivo (mouse) efficacy compare favorably to vancomycin, and they define AJ-024 as a valuable platform for the development of new anti-C. difficile antibiotics.
- 2 December 2021
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 20 (9) , 1893-1899
Diversity-oriented routes to thiopeptide antibiotics: total synthesis and biological evaluation of micrococcin P2
We report the first total synthesis of micrococcin P2 (MP2, 1) by a diversity-oriented route that incorporates a number of refinements relative to earlier syntheses. Biological data regarding the activity of 1 against a range of human pathogens are also provided. Furthermore, we disclose a chemical property of MP2 that greatly facilitates medicinal chemistry work in the micrococcin area and describe a method to obtain MP2 by fermentation in B. subtilis.
- 2 December 2021
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 20 (9) , 1893-1899
Diversity-oriented routes to thiopeptide antibiotics: total synthesis and biological evaluation of micrococcin P2
We report the first total synthesis of micrococcin P2 (MP2, 1) by a diversity-oriented route that incorporates a number of refinements relative to earlier syntheses. Biological data regarding the activity of 1 against a range of human pathogens are also provided. Furthermore, we disclose a chemical property of MP2 that greatly facilitates medicinal chemistry work in the micrococcin area and describe a method to obtain MP2 by fermentation in B. subtilis.